Skip to main content

Table 3 Confounding factors that influence the recurrence prevention effectiveness of the c.1018G > A SNV in PINK1

From: PTEN-induced kinase 1 gene single-nucleotide variants as biomarkers in adjuvant chemotherapy for colorectal cancer: a retrospective study

 

Recurrence (n = 26a)

Non-recurrence (n = 57)

p-value

PINK1

 c.1018A (n = 35) (%)

5 (19.2)

30 (52.6)

0.01

 c.1018G (n = 48) (%)

21 (80.8)

27 (47.4)

 

Pathological histotype

  

0.89

 Non poor (%)

17 (65.4)

33 (57.9)

 

 Poor (%)

9 (34.6)

24 (42.1)

 

Location

  

0.53

 Right (%)

7 (26.9)

19 (33.3)

 

 Left (%)

19 (73.1)

38 (66.7)

 

Depth

  

0.79

  < T4 (%)

19 (73.1)

49 (86.0)

 

  ≥ T4 (%)

7 (26.9)

8 (14.0)

 

Stage

  

0.23

 II (%)

5 (19.2)

4 (7.0)

 

 III (%)

21 (80.8)

53 (93.0)

 

Adjuvant regimenb

  

0.95

 Oxaliplatin combination (%)

7 (26.9)

13 (22.8)

 

 Others (%)

19 (73.1)

44 (77.2)

 
  1. Logistic regression was performed to test for confounding effects on the relationship between a PINK1 SNV (c.1018G > A) and non-recurrence of CRC
  2. aNeither c.1018A nor c.1018G were detected in one case of recurrence
  3. bOxaliplatin combination: FOLFOX (5-FU, levofolinate, oxaliplatin):1, CAPOX (capecitabine, oxaliplatin):18, SOX (S-1, oxaliplatin):1
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us